Compare Amgen, Inc. (AMGN) vs NICE Ltd (NICE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs NICE Ltd — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while NICE Ltd trades at $100.04 (market cap $5.87B). The key difference: Amgen, Inc. is far larger — about 33.4× NICE Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| AMGN | NICE | |
|---|---|---|
Market Cap | $196.12B | $5.87B |
Sector | Health | Technology |
52-Week High | $388.16 | $170.37 |
52-Week Low | $271.18 | $83.15 |
Enterprise Value | $241.41B | $5.65B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NICE trades at $99.74, up 1.92% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with a P/E of 11.82 suggesting potential undervaluation. Recent news highlights expansion in AI-powered customer experience solutions, including partnerships and AWS integration, driving positive sentiment.
The outlook is positive with a consensus price target of $124.88, implying significant upside. Risks include competitive pressures in the software sector and potential margin compression as revenue growth moderates. Institutional ownership trends and bullish analyst ratings support a favorable investment case, though market volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
